| 0.6484 -0.016 (-2.35%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.79  |
1-year : | 0.86 |
| Resists | First : | 0.68 |
Second : | 0.74 |
| Pivot price | 0.66 |
|||
| Supports | First : | 0.58 | Second : | 0.48 |
| MAs | MA(5) : | 0.63  |
MA(20) : | 0.66 |
| MA(100) : | 0.69 |
MA(250) : | 1.82 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.7 |
D(3) : | 39 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 3.47 | Low : | 0.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PPBT ] has closed above bottom band by 37.3%. Bollinger Bands are 74.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 45 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.67 - 0.67 | 0.67 - 0.68 |
| Low: | 0.63 - 0.63 | 0.63 - 0.64 |
| Close: | 0.64 - 0.65 | 0.65 - 0.65 |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Wed, 07 Jan 2026
Experimental cancer antibody stays safer even at 300x dose - Stock Titan
Thu, 11 Dec 2025
Purple Biotech Announces Positive Preclinical Data at ESMO IO Congress 2025 - TipRanks
Thu, 04 Dec 2025
Purple Biotech to Present New Preclinical Data from its - GlobeNewswire
Fri, 14 Nov 2025
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Wed, 29 Oct 2025
Purple Biotech’s Impressive Leap: What’s Driving It? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 849 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 160 (K) |
| Shares Short P.Month | 260 (K) |
| EPS | -46.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -10.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | 16.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|